Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.
4 reports, 2 independent
Updated Oct 6
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Price targets were cut, lifted, and increased by TD Cowen, Morgan Stanley, and Citigroup.1 source
Analyst firms upgraded ratings for Royalty Pharma; updates include target price hikes and 'buy' ratings.1 source
Keep exploring
The entities involved
-
Royalty Pharma
biopharmaceutical company based in New York City
-
Citigroup
American investment bank and financial services corporation
-
Morgan Stanley
U.S. investment bank
-
TD Cowen
American investment bank
Related events
- Multiple financial institutions, including Morgan Stanley, Citigroup, and TD Cowen, boosted price targets and upgraded ratings on October 16, 2026.
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- Citigroup boosted its price target and gave a buy rating for Wholesale Club, with MarketBeat providing consensus data.
- TD Cowen provided analyst ratings and price targets for Werner Enterprises, while Citigroup also lifted its price target based on company performance.
- Citigroup and Jefferies Financial Group raised their price targets and issued buy ratings for Beauty.